hero section gradient
4 handpicked stocks

China AI

Once overlooked, Chinese tech giants are now the new darlings of global investors. This collection features companies positioned to become AI champions in the world's second-largest economy, carefully selected by our expert analysts.

Author avatar

Han Tan | Market Analyst

Published on May 5

Your Basket's Financial Footprint

This basket's total market capitalisation is 676075.65 and is heavily anchored by a few very large-cap positions, creating a concentrated large-cap profile.

Key Takeaways for Investors:
  • Large-cap dominance suggests lower volatility and tendency to track broader markets, implying generally more stable returns than small-cap baskets.
  • Suitably used as a core, diversified holding for long-term allocation rather than a speculative, short-term trade.
  • Expect gradual, long-term appreciation rather than explosive short-term gains; growth likely to be steady and measured.
Total Market Cap
  • BABA: $397.68B

  • BIDU: $40.96B

  • JD: $51.88B

  • Other

About This Group of Stocks

1

Our Expert Thinking

DeepSeek's AI breakthrough sparked investor excitement for Chinese tech stocks. Global markets are betting these companies can develop cost-effective AI models while potentially replicating the success of US tech giants like Nvidia, Meta, and Microsoft.

2

What You Need to Know

Chinese tech companies are rapidly increasing AI investments and forming strategic partnerships rather than solely developing in-house solutions. Their nimble approach and access to China's vast market could provide unique advantages in the global AI race.

3

Why These Stocks

These specific companies represent China's technology leaders with significant AI commitments and resources. Each is actively integrating AI into their platforms and services, positioning themselves at the forefront of China's artificial intelligence ambitions.

Why You'll Want to Watch These Stocks

🚀

The DeepSeek Effect

DeepSeek's breakthrough sparked a frenzy, with Tencent surging 15% after announcing plans to integrate the technology into Weixin. This could be just the beginning of a larger AI revolution in China.

💡

From Overlooked to Opportunity

These once unloved Chinese tech giants are rapidly transforming into AI champions. Could they follow the stellar trajectory of US counterparts like Nvidia and Microsoft?

🔍

Innovation at Lower Costs

China's approach to developing cheaper, nimbler AI models could disrupt the global market. Experts are closely watching these companies for signs of competitive advantages.

Get the full story on this Basket. Read our detailed article on its risks and potential.

Read Full Insight

Why Invest with Nemo Money?

Nemo Logo Fade
🆓

Zero Commission

Trade stocks, ETFs, and more with zero commission. Keep more of your returns.

🔒

Trusted & Regulated

Part of Exinity Group 2015, serving over a million customers globally.

🚀

6% Interest on Cash

Earn 6% AER on uninvested cash with daily interest payments.

Discover More Opportunities

Global Infrastructure Partners: UAE Exposure Risks

Global Infrastructure Partners: UAE Exposure Risks

The UAE's strategic push for economic diversification and smart city development is creating significant demand for advanced construction and infrastructure solutions. This basket provides exposure to a selection of US and EU-listed companies that supply essential materials, technology, and engineering services to the region's projects.

UAE Infrastructure Global Suppliers Breakdown

UAE Infrastructure Global Suppliers Breakdown

As the UAE continues its ambitious economic diversification, demand for world-class infrastructure creates opportunities for the companies that build it. This basket offers exposure to US and EU-listed industrial, materials, and technology firms that are integral to developing these large-scale projects.

Antiviral M&A Wave: Biotech Opportunities in 2025

Antiviral M&A Wave: Biotech Opportunities in 2025

Merck's $9.2 billion acquisition of Cidara Therapeutics strengthens its antiviral pipeline as a key patent nears expiry. This major deal signals a growing trend of pharmaceutical giants buying smaller biotechs, creating potential opportunities among companies with promising infectious disease therapies.

Frequently Asked Questions